Peptomer Therapeutics has successfully secured startup funding from NIDHI-PRAYAS, a program under the Ministry of Science and Technology. With this funding, our foremost goal is to advance the development of the next generation of peptide antibiotics that effectively target both Gram-positive and Gram-negative bacteria. Here we develop new generation peptides with positive charge on the peptide backbone, thus facilitating electively disrupting bacterial cell walls..
BIG grant from BIRAC
Peptomer Therapeutics has marked a significant achievement by securing a prestigious grant from the Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology. This accomplishment highlights the company’s unwavering commitment to advancing innovative solutions in the battle against Antimicrobial Resistance (AMR). With this substantial funding, Peptomer Therapeutics is primed to expedite its research and development initiatives in the realm of antimicrobial resistance, furthering its impact in the field.
Peptomer has successfully secured startup funding under RKVY-RAFTAAR from the Ministry of Agriculture. The project’s primary objective is to pioneer innovative drug delivery formulations aimed at enhancing the effectiveness of antibiotics and combating drug-resistant mastitis in dairy animals. This initiative holds great promise for improving animal health and addressing challenges posed by Antimicroibal resistane (AMR) in the agricultural sector.
Peptomer has secured a seed fund of ₹ 15 million from founders. To develop new gerantion oligomers and peptidomimetics as alteranties to antbitoics. This support is instrumental in driving our mission to address antimicrobial resistance and advance groundbreaking solutions for healthcare challenges.